Table 1 Demographic and clinical characteristics of the study participants
| Â | DNA methylation | Gene expression | ||
|---|---|---|---|---|
Patients (n = 12) | Controls (n = 12) | Patients (n = 16) | Controls (n = 18) | |
Age at enrollment (mean ± SD) | 52.17 ± 12.1 | 48.58 ± 15.6 | 51.75 ± 12.3 | 49.28 ± 13.9 |
Female, n (%) | 12 (100%) | 12 (100%) | 16 (100%) | 18 (100%) |
dcSSc, n (%) | 6 (50%) | NA | 10 (62.5%) | NA |
lcSSc, n (%) | 5 (41.7%) | NA | 4 (25%) | NA |
ssSSc, n (%) | 1 (8.3%) | NA | 1 (6.25%) | NA |
Raynaud’s Phenomenon, n (%) | 12 (100%) | NA | 16 (100%) | NA |
Disease duration (mean ± SD) | 11.08 ± 6.27 | NA | 8.88 ± 7.78 | NA |
mRSS (mean ± SD)a | 13 ± 6.18 | NA | 13 ± 6.18 | NA |
ILD, n (%) | 8 (66.7%) | NA | 10 (62.5%) | NA |
PH/PAH, n (%) | 5 (41.7%) | NA | 5 (31.3%) | NA |
Overlap MCTD, n (%) | 0 (0%) | NA | 1 (6.25%) | NA |
Overlap SLE, n (%) | 0 (0%) | NA | 1 (6.25%) | NA |
Immunosuppressive medications, n (%) | 8 (66.7%) | NA | 12 (75%) | NA |
Antihypertensive medications, n (%) | 9 (75%) | NA | 13 (81%) | NA |
Smoker at enrollment, n (%)b | 2 (16.7%) | 0 (0%) | 2 (12.5%) | 2 (11.1%) |